Diagnosing NMOSD

AN AQP4-IgG ANTIBODY TEST IS RECOMMENDED FOR DIAGNOSING NMOSD1

Conducting proper antibody testing using a cell-based assay (CBA), and having a full diagnostic workup,* is important to diagnosing NMOSD and distinguishing it from other autoimmune diseases.

AQP4-IgG, aquaporin-4 immunoglobulin G.
This is a hypothetical patient.
*

Diagnostic workup includes a complete medical history and physical exam, labs, electrophysiological analysis, and imaging studies.1

BECAUSE AQP4-IgG+ NMOSD IS THE MOST PREVALENT FORM OF NMOSD, FOLLOW THESE DIAGNOSTIC CRITERIA2,3

Number 1

At least 1 core clinical characteristic2:

  • Optic neuritis
  • Acute myelitis
  • Area postrema syndrome
  • Acute brain stem syndrome
  • Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic magnetic resonance imaging (MRI) lesions
  • Symptomatic cerebral syndrome with NMOSD-typical brain lesions
Number 2

Positive test for AQP4-IgG antibodies2

  • 73% of NMOSD cases are AQP4-IgG+3
Number 3

Exclusion of alternative diagnoses such as multiple sclerosis (MS), sarcoidosis, or neoplasm2

SEVERAL TYPES OF TESTING CAN HELP DETERMINE IF A PATIENT HAS NMOSD1

Medical History and Physical Exam

Perform detailed medical history

Pay special attention to:

  • Brain stem symptoms
  • Neuropathic pain
  • Painful tonic spasms
Laboratory Tests

Blood work

  • Rule out infection and connective disorders

Cerebrospinal fluid (CSF) diagnostics

  • Unlike in MS, most CSF alterations in NMOSD present during acute events and disappear during remission

Serum AQP4-IgG testing

  • Essential and most important test in the diagnosis of NMOSD
  • Confirm with methodologically independent assay
Electrophysiology Analysis

Visual evoked potentials

Median and tibial somatosensory evoked potentials

Motor evoked potentials

Imaging Studies

MRI

  • Image entire central nervous system (CNS)
  • Central longitudinal spinal cord lesions are typical of NMOSD

Optical coherence tomography

  • Useful for imaging unmyelinated CNS axons within the retina

LIVE CBA IS THE PREFERRED METHOD OF TESTING FOR AQP4-IgG+ NMOSD2,4

The likelihood of having a false-negative result with enzyme-linked immunosorbent assay (ELISA) methodology is between 1.5 and 15 times greater when compared to the CBA.4

Live CBAs2

  • Specifically, live CBAs are the preferred method of testing due to high sensitivity and specificity of results and a lower rate of false positives as compared to fixed CBAs and ELISA
  • The International Panel for NMO Diagnosis (IPND) strongly recommends testing with CBAs whenever possible because they optimize autoantibody detection

FALSE NEGATIVES CAN HAPPEN; IF SIGNS POINT TO NMOSD, A RETEST IS RECOMMENDED4

A false negative is more likely to happen if:

  • A patient is recovering from relapse
  • A patient is currently on immunosuppressive therapies
  • A less accurate method of testing was used

If clinical suspicion remains, you may retest 3 to 6 months after a negative result.4

COMMERCIAL REFERENCE LABORATORIES THAT OFFER CELL-BASED ASSAYS FOR NMOSD

Mayo Clinical Laboratories

3050 Superior Dr NW

Rochester, MN 55901

Phone: 1-800-533-1710

Phone: 1-507-266-5700

Fax: 1-507-284-1759

mayocliniclabs.com

NMOSD test code (anti-aquaporin 4 (AQP4) with reflex to anti-MOG)

NMOFS & MOGFS, FACS, Cell sorting
Order both codes


Neurocode USA Lab

3548 Meridian St, Suite 101

Bellingham, WA 98225

Phone: 1-778-991-5350

Fax: 1-604-822-0758

info@neurocode.com

NMOSD test code (anti-aquaporin 4 (AQP4) with reflex to anti-MOG)

Live CBA, STAT (Same-day TAT) IHC on Snap-frozen brains


ARUP
Laboratories

500 Chipeta Way

Salt Lake City, UT 84108

Phone: 1-800-522-2787

clientservices@aruplab.com

NMOSD test code (anti-aquaporin 4 (AQP4) with reflex to anti-MOG)

3001283
IFA


Athena Diagnostics

200 Forest St, 2nd Floor

Marlborough, MA 01752

Phone: 1-800-394-4493, option 2

athenadiagnostics.com/ordering/supplies/requisition-forms

NMOSD test code (anti-aquaporin 4 (AQP4) with reflex to anti-MOG)

1287
CBA


Quest Diagnostics

500 Plaza Dr

Secaucus, NJ 07094

Phone: 1-866-MYQUEST (1-866-697-8378)

questdiagnostics.com

NMOSD test code (anti-aquaporin 4 (AQP4) with reflex to anti-MOG)

38312
IFA


Alexion acquires aggregate, fully anonymized data and relevant information from testing laboratories, including those listed here.
Testing laboratories' provision of data to Alexion did not play a role in the inclusion of those laboratories listed herein. This list was chosen
based on each laboratory's representation that it provides live or fixed cell-based assays for antibodies corresponding to disease states as
listed, and offers reflex testing for minority antibodies where noted. Alexion does not warrant or guarantee the laboratories’
representations
. Alexion is committed to patient privacy and compliance with state and federal privacy laws. Visit the Alexion privacy
notice
.

NMOSD IS OFTEN MISDIAGNOSED
AS MS5

NMOSD VS MS

ATTACKS CAN BE RECURRENT AND MAY PREDICT FUTURE DISABILITY5,6

CYCLE OF ATTACKS
References: 1. Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261(1):1-16. 2. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189. 3. Hamid SHM, Whittam D, Mutch K, et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017;264(10):2088-2094. 4. Waters PJ, Pittock SJ, Bennett JL, Jarius S, Weinshenker BG, Wingerchuk DM. Evaluation of aquaporin-4 antibody assays. Clin Exp Neuroimmunol. 2014;5(3):290-303. 5. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9:14. 6. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012;135(pt 6):1834-1849.